Yoltech Initiates a Dose-Escalation Study for YOLT-204 to Treat β -Thalassemia
Shots:
- Yoltech reported the initiation of a dose-escalation study for YOLT-204 (QD) to evaluate its safety & efficacy as an off-the-shelf treatment of transfusion-dependent beta-thalassemia (TDT) without CT & HSCT
- In preclinical studies, YOLT-204 showed consistent expression of fetal hemoglobin, associated with reduced polymerization of sickle hemoglobin, fewer complications, & lower mortality. These findings highlight its potential as a therapy for TDT & SCD
- YOLT-204 boosts RBC count by targeting the regulatory region of hemoglobin to activate fetal hemoglobin expression via targeted delivery to hematopoietic stem cells using YolTech's lipid nanoparticles
Ref: Prnewswire | Image: Yoltech
Related News:- Novo Nordisk Reports Headline Results from P-IIIb (STEP UP) Study of Semaglutide 7.2mg in Obese Adults without Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
